Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 133

1.

Stopping or maintaining oral anticoagulation in patients undergoing photoselective vaporization of the prostate (SOAP) surgery for benign prostate obstruction: study protocol for a multicentre randomized controlled trial.

Charbonneau H, Pasquié M, Peyronnet B, Descazeaud A, Barry-Delongchamps N, Della Negra E, Mathieu R, Karsenty G, Long JA, Ballereau C, Azzouzi AR, Pradère B, Bruyère F, Fournier G, Lebdai S, Calves J, Corbel L, Vincendeau S, Fiard G, Thuillier C, Descotes JL, Colin P, Culty T, Hesbois A, Fuzier V, Savy N, Pathak A, Albaladejo P, Samama CM, Guerrero F, Misraï V.

Trials. 2018 Dec 27;19(1):705. doi: 10.1186/s13063-018-3066-9.

2.

Radical Prostatectomy after Vascular Targeted Photodynamic Therapy with Padeliporfin: Feasibility, and Early and Intermediate Results.

Pierrard V, Lebdai S, Kleinclauss F, Azzouzi AR, Terrier JE, Fortier E, Joniau S, Van Der Poel H, Salomon G, Casanova J, Medina-Lopez RA, Potiron E, Rigaud J, Vincendeau S, Rassweiler J, Villers A, Gaston R, Saussine C, Giai J, Gaillac B, Emberton M, Ruffion A.

J Urol. 2019 Feb;201(2):315-321. doi: 10.1016/j.juro.2018.08.084.

PMID:
30248343
3.

Study of Renal and Kidney Tumor Vascularization Using Data from Preoperative Three-dimensional Arteriography Prior to Partial Nephrectomy.

Borojeni S, Borojeni A, Panayotopoulos P, Bouvier A, Aubé C, Azzouzi AR, Bigot P.

Eur Urol Focus. 2018 Aug 2. pii: S2405-4569(18)30212-8. doi: 10.1016/j.euf.2018.07.028. [Epub ahead of print]

PMID:
30078544
4.

Laparoscopic Partial Nephrectomy After Selective Embolization and Robot-Assisted Partial Nephrectomy: A Comparison of Short-Term Oncological and Functional Outcomes.

Benoit M, Bouvier A, Panayotopoulos P, Culty T, Guillonneau B, Aube C, Azzouzi AR, Sebe P, Bigot P.

Clin Genitourin Cancer. 2018 Dec;16(6):453-457. doi: 10.1016/j.clgc.2018.07.005. Epub 2018 Jul 12.

PMID:
30072310
5.

Randomized Trial of Partial Gland Ablation with Vascular Targeted Phototherapy versus Active Surveillance for Low Risk Prostate Cancer: Extended Followup and Analyses of Effectiveness.

Gill IS, Azzouzi AR, Emberton M, Coleman JA, Coeytaux E, Scherz A, Scardino PT; PCM301 Study Group.

J Urol. 2018 Oct;200(4):786-793. doi: 10.1016/j.juro.2018.05.121. Epub 2018 Jun 2.

PMID:
29864437
6.

Expanding indication of padeliporfin (WST11) vascular-targeted photodynamic therapy: results of prostate cancer Latin-American multicenter study.

Rodriguez-Rivera JA, Rodriguez-Lay R, Zegarra-Montes L, Benzaghou F, Gaillac B, Azzouzi AR, Reis LO, Palma P.

Actas Urol Esp. 2018 Dec;42(10):632-638. doi: 10.1016/j.acuro.2018.02.009. Epub 2018 Apr 23. English, Spanish.

PMID:
29699883
7.

Medium-term Follow-up of Vascular-targeted Photodynamic Therapy of Localized Prostate Cancer Using TOOKAD Soluble WST-11 (Phase II Trials).

Noweski A, Roosen A, Lebdai S, Barret E, Emberton M, Benzaghou F, Apfelbeck M, Gaillac B, Gratzke C, Stief C, Azzouzi AR.

Eur Urol Focus. 2018 Apr 13. pii: S2405-4569(18)30092-0. doi: 10.1016/j.euf.2018.04.003. [Epub ahead of print]

PMID:
29661587
8.

Transcutaneous tibial nerve stimulation: 2 years follow-up outcomes in the management of anticholinergic refractory overactive bladder.

Leroux PA, Brassart E, Lebdai S, Azzouzi AR, Bigot P, Carrouget J.

World J Urol. 2018 Sep;36(9):1455-1460. doi: 10.1007/s00345-018-2296-5. Epub 2018 Apr 9.

PMID:
29633085
9.

Fatty acid profile in peri-prostatic adipose tissue and prostate cancer aggressiveness in African-Caribbean and Caucasian patients.

Figiel S, Pinault M, Domingo I, Guimaraes C, Guibon R, Besson P, Tavernier E, Blanchet P, Multigner L, Bruyère F, Haillot O, Mathieu R, Vincendeau S, Rioux-Leclercq N, Lebdai S, Azzouzi AR, Perrouin-Verbe MA, Fournier G, Doucet L, Rigaud J, Renaudin K, Mahéo K, Fromont G.

Eur J Cancer. 2018 Mar;91:107-115. doi: 10.1016/j.ejca.2017.12.017.

PMID:
29413967
10.

Prostatic injection of botulinum toxin is not inferior to optimized medical therapy in the management of lower urinary tract symptoms due to benign prostatic hyperplasia: results of a randomized clinical trial.

Robert G, Descazeaud A, Karsenty G, Saussine C, Azzouzi AR, de la Taille A, Desgrandchamps F, Faix A, Fourmarier M, Georget A, Benard A, Barry Delongchamps N.

World J Urol. 2018 Jun;36(6):921-929. doi: 10.1007/s00345-018-2193-y. Epub 2018 Jan 30.

PMID:
29383480
11.

Mesalazine: A Novel Etiology For Drug-Induced Urinary Calculi.

Corbery B, Lebdai S, Borojeni S, Bigot P, Azzouzi AR, Culty T.

Urol J. 2018 May 3;15(3):132-133. doi: 10.22037/uj.v0i0.3902.

12.

Metabolic syndrome and low high-density lipoprotein cholesterol are associated with adverse pathological features in patients with prostate cancer treated by radical prostatectomy.

Lebdai S, Mathieu R, Leger J, Haillot O, Vincendeau S, Rioux-Leclercq N, Fournier G, Perrouin-Verbe MA, Doucet L, Azzouzi AR, Rigaud J, Renaudin K, Charles T, Bruyere F, Fromont G.

Urol Oncol. 2018 Feb;36(2):80.e17-80.e24. doi: 10.1016/j.urolonc.2017.09.026. Epub 2017 Nov 16.

PMID:
29153942
13.

Laparoscopic partial nephrectomy following tumor embolization in a hybrid room. Feasibility and clinical outcomes.

Panayotopoulos P, Bouvier A, Besnier L, Rousselet MC, Nedelcu C, Baize N, Beydon L, Aubé C, Azzouzi AR, Bigot P.

Surg Oncol. 2017 Dec;26(4):377-381. doi: 10.1016/j.suronc.2017.07.012. Epub 2017 Jul 29.

PMID:
29113655
14.

Benefits of Urologic-Dermatologic Consultations for the Diagnosis of Cutaneous Penile Lesions: A Prospective Study.

Fortier E Jr, Cerruti A, Clec'h CL, Azzouzi AR, Bigot P.

Clin Genitourin Cancer. 2018 Apr;16(2):e421-e424. doi: 10.1016/j.clgc.2017.09.013. Epub 2017 Oct 5.

PMID:
29079166
15.

[Focal therapies: An alternative option for low-risk prostate cancer management?]

Lebdai S, Lunelli L, Bigot P, Cussenot O, Azzouzi AR.

Presse Med. 2017 Oct;46(10):935-939. doi: 10.1016/j.lpm.2017.09.012. Epub 2017 Oct 12. French.

PMID:
29031683
16.

Geriatric Assessment Can Predict Outcomes of Endoscopic Surgery for Benign Prostatic Hyperplasia in Elderly Patients.

Pichon T, Lebdai S, Launay CP, Collet N, Chautard D, Cerruti A, Hoarau N, Brassart E, Bigot P, Beauchet O, Azzouzi AR, Culty T.

J Endourol. 2017 Nov;31(11):1195-1202. doi: 10.1089/end.2017.0325.

PMID:
28903581
17.

Evaluation of bleeding risk in patients on anticoagulation for mechanical cardiac valve operated for benign prostatic obstruction.

Gardic S, Misrai V, Azzouzi AR, Campeggi A, Cornu JN, Taille A, Lebdai S, Mathieu R, Robert G, Descazeaud A.

Prog Urol. 2017 Sep;27(10):559-563. doi: 10.1016/j.purol.2017.05.012. Epub 2017 Jun 24.

PMID:
28651993
18.

Perioperative and economic analysis of surgical treatments for benign prostatic hyperplasia: A study of the French committee on LUT.

Mathieu R, Lebdai S, Cornu JN, Benchikh A, Azzouzi AR, Delongchamps NB, Dumonceau O, Faix A, Fourmarier M, Haillot O, Lukacs B, Misrai V, de La Taille A, Robert G, Descazeaud A.

Prog Urol. 2017 May;27(6):362-368. doi: 10.1016/j.purol.2017.03.010. Epub 2017 May 8.

PMID:
28495071
19.

[Urinary catheters prevalence study in a university hospital].

Carrouget J, Legeay C, Poirier A, Azzouzi AR, Zahar JR, Bigot P.

Prog Urol. 2017 Apr;27(5):305-311. doi: 10.1016/j.purol.2017.03.006. Epub 2017 Apr 7. French.

PMID:
28392431
20.

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer - Authors' reply.

Azzouzi AR, Emberton M; PCM301 study investigators.

Lancet Oncol. 2017 Apr;18(4):e188. doi: 10.1016/S1470-2045(17)30163-8. No abstract available.

PMID:
28368250
21.

Vascular Targeted Photodynamic Therapy with Padeliporfin for Low Risk Prostate Cancer Treatment: Midterm Oncologic Outcomes.

Lebdai S, Bigot P, Leroux PA, Berthelot LP, Maulaz P, Azzouzi AR.

J Urol. 2017 Aug;198(2):335-344. doi: 10.1016/j.juro.2017.03.119. Epub 2017 Mar 18.

PMID:
28322857
22.

Padeliporfin vascular-targeted photodynamic therapy versus active surveillance in men with low-risk prostate cancer (CLIN1001 PCM301): an open-label, phase 3, randomised controlled trial.

Azzouzi AR, Vincendeau S, Barret E, Cicco A, Kleinclauss F, van der Poel HG, Stief CG, Rassweiler J, Salomon G, Solsona E, Alcaraz A, Tammela TT, Rosario DJ, Gomez-Veiga F, Ahlgren G, Benzaghou F, Gaillac B, Amzal B, Debruyne FM, Fromont G, Gratzke C, Emberton M; PCM301 Study Group.

Lancet Oncol. 2017 Feb;18(2):181-191. doi: 10.1016/S1470-2045(16)30661-1. Epub 2016 Dec 20.

23.

How Did We Obtain Complete Remission in Patients Who Had Metastatic Renal Cancer in the Era of Targeted Therapies?

Brécheteau F, Lebdai S, Carrouget J, Lebigot J, Nedelcu C, Rousselet MC, Baize N, Azzouzi AR, Bigot P.

Ann Surg Oncol. 2017 Feb;24(2):369-374. doi: 10.1245/s10434-016-5587-3. Epub 2016 Sep 23.

PMID:
27663564
24.

Reply by the Authors.

Mougin J, Souday V, Azzouzi AR, Bigot P.

Urology. 2016 Oct;96:178-179. doi: 10.1016/j.urology.2016.06.030. Epub 2016 Jun 28. No abstract available.

PMID:
27369819
25.

Final Results of a Phase I/II Multicenter Trial of WST11 Vascular Targeted Photodynamic Therapy for Hemi-Ablation of the Prostate in Men with Unilateral Low Risk Prostate Cancer Performed in the United States.

Taneja SS, Bennett J, Coleman J, Grubb R, Andriole G, Reiter RE, Marks L, Azzouzi AR, Emberton M.

J Urol. 2016 Oct;196(4):1096-104. doi: 10.1016/j.juro.2016.05.113. Epub 2016 Jun 9.

26.

Correlation between prostate volume and single nucleotide polymorphisms implicated in the steroid pathway.

Cornu JN, Audet-Walsh E, Drouin S, Bigot P, Valeri A, Fournier G, Azzouzi AR, Roupret M, Cormier L, Chanock S, Guillemette C, Cussenot O, Lévesque E, Cancel-Tassin G.

World J Urol. 2017 Feb;35(2):293-298. doi: 10.1007/s00345-016-1869-4. Epub 2016 Jun 8.

PMID:
27277477
27.

Evaluation of Hyperbaric Oxygen Therapy in the Treatment of Radiation-induced Hemorrhagic Cystitis.

Mougin J, Souday V, Martin F, Azzouzi AR, Bigot P.

Urology. 2016 Aug;94:42-6. doi: 10.1016/j.urology.2016.04.015. Epub 2016 Apr 25.

PMID:
27125879
28.

Standardization of definitions in focal therapy of prostate cancer: report from a Delphi consensus project.

Postema AW, De Reijke TM, Ukimura O, Van den Bos W, Azzouzi AR, Barret E, Baumunk D, Blana A, Bossi A, Brausi M, Coleman JA, Crouzet S, Dominguez-Escrig J, Eggener S, Ganzer R, Ghai S, Gill IS, Gupta RT, Henkel TO, Hohenfellner M, Jones JS, Kahmann F, Kastner C, Köhrmann KU, Kovacs G, Miano R, van Moorselaar RJ, Mottet N, Osorio L, Pieters BR, Polascik TJ, Rastinehad AR, Salomon G, Sanchez-Salas R, Schostak M, Sentker L, Tay KJ, Varkarakis IM, Villers A, Walz J, De la Rosette JJ.

World J Urol. 2016 Oct;34(10):1373-82. doi: 10.1007/s00345-016-1782-x. Epub 2016 Feb 18. Review.

29.

Impact of Body Mass Index, Age, Prostate Volume, and Genetic Polymorphisms on Prostate-specific Antigen Levels in a Control Population.

Cornu JN, Cancel-Tassin G, Cox DG, Roupret M, Koutlidis N, Bigot P, Valeri A, Ondet V, Gaffory C, Fournier G, Azzouzi AR, Cormier L, Cussenot O.

Eur Urol. 2016 Jul;70(1):6-8. doi: 10.1016/j.eururo.2016.01.027. Epub 2016 Feb 2.

PMID:
26850968
30.

Impact of retrograde flexible ureteroscopy and intracorporeal lithotripsy on kidney functional outcomes.

Hoarau N, Martin F, Lebdai S, Chautard D, Culty T, Azzouzi AR, Bigot P.

Int Braz J Urol. 2015 Sep-Oct;41(5):920-6. doi: 10.1590/S1677-5538.IBJU.2014.0402.

31.

Partial nephrectomy after selective embolization of tumor vessels in a hybrid operating room: A new approach of zero ischemia in renal surgery.

Bigot P, Bouvier A, Panayotopoulos P, Aubé C, Azzouzi AR.

J Surg Oncol. 2016 Feb;113(2):135-7. doi: 10.1002/jso.24120. Epub 2015 Dec 10.

PMID:
26659385
32.

[Medicoeconomic aspects of benign prostatic hyperplasia medical treatment].

Lebdai S, Azzouzi AR, Delongchamps NB, Benchikh A, Campeggi A, Cornu JN, Dumonceau O, Faix A, Fourmarier M, Haillot O, Lukacs B, Mathieu R, Misrai V, Robert G, de La Taille A, Descazeaud A.

Prog Urol. 2016 Feb;26(2):129-36. doi: 10.1016/j.purol.2015.10.010. Epub 2015 Nov 28. Review. French.

PMID:
26643518
33.

[Editorial comment to: Urinary PCA3 to predict prostate cancer in a cohort of 1015 patients].

Bigot P, Lebdai S, Azzouzi AR.

Prog Urol. 2015 Dec;25(16):1169-70. doi: 10.1016/j.purol.2015.09.001. Epub 2015 Oct 9. French. No abstract available.

PMID:
26455777
34.

Posterior Spinal Cord Syndrome after Flexible Ureteroscopy for Kidney Stones.

Carrouget J, Ammi M, Nedelcu C, Cassereau J, Lebdai S, Azzouzi AR, Bigot P.

Urol Int. 2016;96(1):116-8. doi: 10.1159/000439138. Epub 2015 Sep 5.

PMID:
26340745
35.

[Serious and unexpected complications of benign prostatic obstruction surgery: Results of the LUTS Committee survey from urologists of the French Urological Association].

Misraï V, Barry Delongchamps N, Lebdai S, Azzouzi AR, Benchikh A, Cornu JN, Dumonceau O, Fourmarier M, Haillot O, Lukacs B, Mathieu R, Robert G, de La Taille A, Descazeaud A.

Prog Urol. 2015 Sep;25(10):583-9. doi: 10.1016/j.purol.2015.06.006. Epub 2015 Jul 7. French.

PMID:
26159052
36.

The subclassification of papillary renal cell carcinoma does not affect oncological outcomes after nephron sparing surgery.

Bigot P, Bernhard JC, Gill IS, Vuong NS, Verhoest G, Flamand V, Reix B, Suer E, Gökce I, Beauval JB, Nouhaud FX, Eto M, Baco E, Matsugasumi T, Chowaniec Y, Rigaud J, Lenormand C, Pfister C, Hetet JF, Ploussard G, Roupret M, Léon P, Bakri AE, Larré S, Tillou X, Doerfler A, Descazeaud A, Koutlidis N, Schneider A, Sebe P, Ingels A, Azzouzi AR, Soulié M, Méjean A, Bensalah K, Patard JJ; members of the Kidney Cancer group of the CCAFU.

World J Urol. 2016 Mar;34(3):347-52. doi: 10.1007/s00345-015-1634-0. Epub 2015 Jul 7.

PMID:
26149352
37.

Nephrectomy improves overall survival in patients with metastatic renal cell carcinoma in cases of favorable MSKCC or ECOG prognostic features.

Mathieu R, Pignot G, Ingles A, Crepel M, Bigot P, Bernhard JC, Joly F, Guy L, Ravaud A, Azzouzi AR, Gravis G, Chevreau C, Zini L, Lang H, Pfister C, Lechevallier E, Fais PO, Berger J, Vayleux B, Roupret M, Audenet F, Descazeaud A, Rigaud J, Machiels JP, Staehler M, Salomon L, Ferriere JM, Kleinclauss F, Bensalah K, Patard JJ.

Urol Oncol. 2015 Aug;33(8):339.e9-15. doi: 10.1016/j.urolonc.2015.05.014. Epub 2015 Jun 16.

PMID:
26087971
38.

Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers.

van der Poel H, Klotz L, Andriole G, Azzouzi AR, Bjartell A, Cussenot O, Hamdy F, Graefen M, Palma P, Rivera AR, Stief CG.

World J Urol. 2015 Jul;33(7):907-16. doi: 10.1007/s00345-015-1603-7. Epub 2015 Jun 3.

PMID:
26037891
39.

Editorial Comment to Role of cytoreductive nephrectomy for Japanese patients with primary renal cell carcinoma in the cytokine and targeted therapy era.

Bigot P, Lebdai S, Azzouzi AR.

Int J Urol. 2015 Aug;22(8):740-1. doi: 10.1111/iju.12818. Epub 2015 May 26. No abstract available.

40.

Effect of Sulforaphane in Men with Biochemical Recurrence after Radical Prostatectomy.

Cipolla BG, Mandron E, Lefort JM, Coadou Y, Della Negra E, Corbel L, Le Scodan R, Azzouzi AR, Mottet N.

Cancer Prev Res (Phila). 2015 Aug;8(8):712-9. doi: 10.1158/1940-6207.CAPR-14-0459. Epub 2015 May 12.

41.

Acute renal colic during pregnancy: management and predictive factors.

N'gamba M, Lebdai S, Hasting C, Panayotopoulos P, Ammi M, Sentilhes L, Descamps P, Azzouzi AR, Bigot P.

Can J Urol. 2015 Apr;22(2):7732-8.

PMID:
25891338
42.

[Guide dedicated to general practitioner for the management of lower urinary tract symptoms related to benign prostatic hyperplasia].

Descazeaud A, Barry Delongchamps N, Cornu JN, Azzouzi AR, Buchon D, Benchikh A, Coloby P, Dumonceau O, Fourmarier M, Haillot O, Lebdai S, Mathieu R, Misrai V, Saussine C, de La Taille A, Robert G; Comité des troubles mictionnels de l’homme de l’Association française d’urologie (CTMH-AFU).

Prog Urol. 2015 Jun;25(7):404-12. doi: 10.1016/j.purol.2015.02.008. Epub 2015 Apr 2. French.

PMID:
25841758
43.

Vascular-targeted photodynamic therapy with TOOKAD® Soluble in localized prostate cancer: standardization of the procedure.

Azzouzi AR, Lebdai S, Benzaghou F, Stief C.

World J Urol. 2015 Jul;33(7):937-44. doi: 10.1007/s00345-015-1535-2. Epub 2015 Mar 19.

44.

Multicentre prospective evaluation of the learning curve of holmium laser enucleation of the prostate (HoLEP).

Robert G, Cornu JN, Fourmarier M, Saussine C, Descazeaud A, Azzouzi AR, Vicaut E, Lukacs B.

BJU Int. 2016 Mar;117(3):495-9. doi: 10.1111/bju.13124. Epub 2015 Aug 22.

45.

[Do postoperative drainage types modify outcomes after retrograde intrarenal surgery?].

Cerruti A, Lebdai S, Martin F, Hoarau N, Chautard D, Culty T, Azzouzi AR, Bigot P.

Prog Urol. 2015 May;25(6):331-5. doi: 10.1016/j.purol.2015.01.017. Epub 2015 Mar 5. French.

PMID:
25748790
46.

TOOKAD® Soluble focal therapy: pooled analysis of three phase II studies assessing the minimally invasive ablation of localized prostate cancer.

Azzouzi AR, Barret E, Bennet J, Moore C, Taneja S, Muir G, Villers A, Coleman J, Allen C, Scherz A, Emberton M.

World J Urol. 2015 Jul;33(7):945-53. doi: 10.1007/s00345-015-1505-8. Epub 2015 Feb 25.

47.

Feasibility, safety, and efficacy of salvage radical prostatectomy after Tookad® Soluble focal treatment for localized prostate cancer.

Lebdai S, Villers A, Barret E, Nedelcu C, Bigot P, Azzouzi AR.

World J Urol. 2015 Jul;33(7):965-71. doi: 10.1007/s00345-015-1493-8. Epub 2015 Jan 23.

PMID:
25614256
48.

Post-treatment MRI aspects of photodynamic therapy for prostate cancer.

Kulik M, Nedelcu C, Martin F, Lebdai S, Rousselet MC, Azzouzi AR, Aubé C.

Insights Imaging. 2014 Dec;5(6):697-713. doi: 10.1007/s13244-014-0359-8. Epub 2014 Oct 7.

49.

[Conservative treatment of male non-neurologic urinary incontinence: a review by the LUTS committee of the French Urological Association].

Lebdai S, Delongchamps NB, Azzouzi AR, Benchikh A, Campeggi A, Cornu JN, Dumonceau O, Faix A, Fourmarier M, Haillot O, Lukacs B, Mathieu R, Misrai V, Robert G, de La Taille A, Descazeaud A.

Prog Urol. 2014 Sep;24(10):610-5. doi: 10.1016/j.purol.2014.01.003. Epub 2014 Feb 14. Review. French.

PMID:
25214288
50.

[Treatment of localized prostate cancer by vascular-targeted photodynamic therapy with WST11].

Lebdai S, Martin F, Bigot P, Azzouzi AR.

Prog Urol. 2014 Nov;24(14):911-4. doi: 10.1016/j.purol.2014.08.002. Epub 2014 Sep 5. French.

PMID:
25195031

Supplemental Content

Loading ...
Support Center